TARGETED PARATHYROID GLAND REDUCTION AND LONG-TERM METABOLIC CONTROL OF TERTIARY HYPERPARATHYROIDISM

2014 ◽  
Vol 63 (5) ◽  
pp. B46
Author(s):  
J H Parr

Serum concentration of free T3 and, in female patients, FT4, were found to be lower in 20 asymptomatic, moderately-poor or well controlled, diabetics treated with insulin than in a group of non-diabetic subjects. Over a mean 3-month period of the study a significant fall occurred in HbA1 concentration in both groups of diabetics without change in free thyroid hormone levels. The mean capillary blood glucose, fasting free insulin and fasting lipid concentrations, other than high density lipoprotein (HDL) cholesterol, did not change. No correlations were found between the changes in HbA1 and free thyroid hormone concentrations. Improvement in long term metabolic control did not influence free thyroid hormone levels in well controlled and moderately-poor controlled diabetics, taking insulin.


2014 ◽  
Vol 125 (4) ◽  
pp. 894-897 ◽  
Author(s):  
Tom Shokri ◽  
Susie Q. Lew ◽  
Nader Sadeghi

2009 ◽  
Vol 88 (2) ◽  
pp. 160-169 ◽  
Author(s):  
Hong Cui ◽  
Carol Tucker-Burden ◽  
Sean M. D. Cauffiel ◽  
Adrienne K. Barry ◽  
Neal N. Iwakoshi ◽  
...  

1992 ◽  
Vol 3 (4) ◽  
pp. 1008-1017 ◽  
Author(s):  
E R Gagné ◽  
P Ureña ◽  
S Leite-Silva ◽  
J Zingraff ◽  
A Chevalier ◽  
...  

A retrospective study was performed in chronic hemodialysis patients comparing total parathyroidectomy (PTX) followed by immediate autografting (IA) (total PTX+IA) with subtotal parathyroidectomy (subtotal PTX). One hundred six patients with severe, uncontrolled hyperparathyroidism were referred to this center and underwent surgery during the period from 1980 to 1990. Long-term follow-up after PTX was available in 49 of them: 28 patients had total PTX+IA and 21 had subtotal PTX. The two surgical methods were evaluated with respect to preoperative severity of hyperparathyroidism, immediate postoperative results, and long-term parathyroid status, as evaluated by an RIA measuring intact immunoreactive parathyroid hormone (intact iPTH; normal values, 15 to 65 pg/mL). The initial degree of hyperparathyroidism was comparable in the two groups. An excellent short-term control of hyperparathyroidism was achieved in the great majority (95%) of patients with either surgical procedure. However, long-term normalization of parathyroid gland activity was achieved in only one third of patients whereas 33% had elevated intact iPTH levels (> 130 pg/mL; i.e., higher than twice the upper range of normal) and 32% had low intact iPTH levels (< 15 pg/mL), consistent with permanent hypoparathyroidism. No difference was found in the immediate failure rates: 0 of 28 cases after total PTX+IA compared with 2 of 21 cases after subtotal PTX. Similarly, long-term intact iPTH levels were comparable: 400 +/- 105 versus 212 +/- 82 pg/mL (mean +/- SE; P = not significant). Interestingly, long-term serum intact iPTH levels were higher in patients with nodular (N = 18) than with diffusely (N = 26) hyperplastic glands: 556 +/- 146 versus 126 +/- 52 pg/mL (P < 0.001) and recurrence of hyperparathyroidism was more frequent with nodular hyperplasia (11 of 18) than with diffuse hyperplasia (4 of 26) (P < 0.02). In conclusion, although excellent short-term results were obtained with both procedures, satisfactory long-term control of parathyroid gland function was achieved in only one third of the patients, the other two third remaining either hypoparathyroid or developing recurrent hyperparathyroidism. Last, the histological subtype of parathyroid glands was partially predictive of the recurrence of hyperparathyroidism.


2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Glaucia S. Tres ◽  
Sandra C. Fuchs ◽  
Fabiana Piovesan ◽  
Patricia Koehler-Santos ◽  
Fernanda dos S. Pereira ◽  
...  

Introduction. Studies have shown that T2DM is an inflammatory disease. Thus, the present study was aimed at evaluating whether diacerein could improve the metabolic and inflammatory profile among patients with T2DM under long-term treatment with glucose-lowering agents. Methods. This is a double-blind, parallel, placebo-controlled trial with 72 participants randomly assigned to diacerein 50 mg or placebo for 12 weeks. The primary endpoint was the between-group difference in change in HbA1c. Secondary endpoints included the proportion of patients achieving metabolic control [HbA1c≤7.0% (53 mmol/mol)] and change in inflammatory mediators. Results. Participants in the diacerein group had greater reductions in mean HbA1c level in comparison to placebo (−0.98; 95% CI: −2.02 to 0.05, P=0.06), independently of confounding factors. The difference in HbA1c level was −1.3 (95% CI: −2.3 to −0.4) in favor of diacerein (P=0.007) in those with <14 years of diabetes duration versus 0.05 (−0.7 to 0.8; P=0.9) in those with longer duration. The diacerein group had a 50% increase in the number of participants at the lowest TNF-α level (≤1.46 pg/mL). Conclusions. In patients with long-established T2DM under long-term treatment with glucose-lowering agents, diacerein improves metabolic control as measured by HbA1c level and has a favorable impact on inflammatory profile. Clinical Trial Registry. This trial is registered with Brazilian Clinical Trials Registry (ReBEC) number RBR-29j956.


2010 ◽  
Vol 34 (2) ◽  
pp. e24-e29 ◽  
Author(s):  
F. J. Vílchez-López ◽  
F. Carral-Sanlaureano ◽  
C. Coserria-Sánchez ◽  
A. Nieto ◽  
S. Jiménez ◽  
...  

1997 ◽  
Vol 17 (2) ◽  
pp. 118-123 ◽  
Author(s):  
Sameer Huraib ◽  
Hassan Abu-Aisha ◽  
Jamal Abed ◽  
Jamal Al Wakeel ◽  
Mahmoud Al Desouki ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document